🔎 Trials Near Me

Avaleht › Burkitti lümfoom › Utah

Burkitti lümfoom kliinilised uuringud osariigis Utah

7 uuringut haiguse Burkitti lümfoom jaoks otsivad osalejaid osariigis Utah.

Linnad osariigis Utah

Ametlik uuringutekst (inglise keeles)

A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

  • Primary Children's Hospital, Salt Lake City
VärbamineFaas 2
366 Days – 46 Years · Kõik sood · Uuendatud 2. okt 2026 · NCT06124157

Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia

  • Huntsman Cancer Institute/University of Utah, Salt Lake City
VärbamineFaas 3
Vanused 18–39 · Kõik sood · Uuendatud 2. okt 2026 · NCT03150693

Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)

  • Intermountain - Primary Children's Hospital ( Site 1014), Salt Lake City
VärbamineFaas 1/2
6 Months – 25 Years · Kõik sood · Uuendatud 17. sept 2026 · NCT06395103

A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)

  • Primary Children's Hospital, Salt Lake City
VärbamineFaas 1
Vanused 0–18 · Kõik sood · Uuendatud 16. sept 2026 · NCT06173518

A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

  • Primary Children's Hospital, Salt Lake City
VärbamineFaas 2
Vanused 1–30 · Kõik sood · Uuendatud 1. sept 2026 · NCT04546399

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

  • Primary Children's Hospital, Salt Lake City
VärbamineFaas 3
365 Days – 25 Years · Kõik sood · Uuendatud 25. aug 2026 · NCT03959085

Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL

  • Primary Children's Hospital, Salt Lake City
VärbamineFaas 2
Vanused 7–25 · Kõik sood · Uuendatud 19. aug 2026 · NCT05082519

Allikas ClinicalTrials.gov, andmed saadud 5. okt 2026. Igal uuringul on oma osalemiskõlblikkuse tingimused; uuringumeeskond otsustab, kes saab osaleda.